针对高级软组织肉瘤的基于杰米西塔的化疗:确定适当的剂量和时间表
Kenji Nakano1, Naomi Hayashi2,1, Xiofei Wang1
1Medical Oncology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, JPN.
Cureus
|January 21, 2025
概括
葛西他-多克塞尔 (GEM-DOC) 疗法对晚期软组织肉瘤 (STS) 有潜在的疗效,但具有更高的毒性. 需要进行进一步的试验,以优化这种含有gemcitabine的治疗方案的剂量.
科学领域:
- 在瘤学瘤学.
- 医学瘤学 医学瘤学
- 药理学 药理学是指药理学的学科.
背景情况:
- 针对复发性/转移性软组织肉瘤 (STS) 的gemcitabine-docetaxel (GEM-DOC) 治疗费用的补偿在2024年在日本建立.
- 这项研究回顾性地评估了在此补偿之前使用的含格姆西塔的非标签化疗方案.
研究的目的:
- 评估与先进/转移性软组织肉瘤 (STS) 患者的gemcitabine-docetaxel (GEM-DOC) 治疗与gemcitabine单一治疗相比的疗效和安全性.
- 评估结果,包括客观反应率 (ORR),无进展生存率 (PFS) 和整体生存率 (OS).
主要方法:
- 在2007年2月至2019年10月期间治疗的115名晚期/转移性STS患者的临床记录的回顾性审查.
- 用GEM-DOC (51名患者) 和gemcitabine单疗 (64名患者) 治疗患者之间的结局比较.
主要成果:
- 与gemcitabine单独治疗相比,GEM-DOC治疗显示出更高的客观应答率 (9.8%vs4.7%),无进展生存时间 (3.8vs2.1个月) 和整体生存时间 (21.5vs11.8个月).
- GEM-DOC与显著更高的严重不良事件 (3级或更高) 相关,特别是血液毒性 (80.4%vs40.6%).
结论:
- 特定剂量的GEM-DOC (GEM 900-DOC 70) 可能是有效的高级/转移性STS,但携带更高的毒性负担.
- 有必要进行前性临床试验,以确定最佳的剂量策略,并管理STS治疗中GEM-DOC的毒性.
相关概念视频
Rous Sarcoma Virus (RSV) and Cancer
5.2K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.2K
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
386
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
386


